Jump to Navigation

In April 2005, the FDA recommended that Pfizer Inc. withdraw Bextra, a prescription painkiller, from the market. Bextra, with active ingredient valdecoxib, was marketed as a relief for pain associated with osteoarthritis and rheumatoid arthritis in adults, as well as for discomfort associated with menstrual cycles. Individuals taking the drug experienced serious, and sometimes fatal, side effects. Bextra led to heart failure, liver damage and stomach ulcers that bled. The drug was also linked to a grave skin disease. The FDA had approved Bextra for distribution in the United States on November 16, 2001. A subsequent FDA News advisory directed consumers to stop taking Bextra and call a doctor immediately if they experience stomach ulcers, skin disorder or liver damage. Signs of ulcers include burning stomach pain, black bowel movements that look like tar, and vomit that looks like blood or coffee grounds.

Some of the warning signs of liver damage are nausea, vomiting, tiredness, loss of appetite, itching, yellow coloring of skin or eyes, "flu-like" symptoms and dark urine. If you have used or are using Bextra and have had any of these side effects or other side effects, please obtain a Free Consultation by submitting our online form, or by calling 866-273-1941.

OFFICE LOCATION: 707 Grant Street, Suite 2500 | Pittsburgh, PA 15219 | Phone: 866-273-1941 | Fax: 412-281-4229 | Email Us | Get Directions